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Systemic Lupus Erythematosus (SLE), a chronic, com-
plex disease, is the prototype for systemic human auto-
immune diseases. Although environmental factors are
crucial in triggering the condition, twin and family
studies, as well as genetic linkage and association stu-
dies, have established its strong genetic predisposition.
During the past few years, there has been considerable
interest in identifying genomic segments linked to
SLE through either a whole genome scan or a candidate
gene approach. The discoid lupus erythematosus (DLE)
skin lesion is one of the major, and discriminating,
manifestations in SLE, especially in African American
patients. In this study we have identi¢ed 58 multiplex
families27 African American, 26 European Ameri-
can, and 5 otherswhere at least one SLE patient is also
reported to be a¥icted with DLE. These families were
chosen from the collection of families that are part of
our ongoing linkage study for SLE. A genome-wide
parametric and nonparametric linkage analysis was
conducted with 320 markers. Signi¢cant evidence of
linkage was identi¢ed in only one chromosomal loca-
tion, 11p13, in the African American families. The max-
imum 2-point linkage was 5.6 in these pedigrees,
obtained at a marker located 47 cM away from the p-
terminal end of chromosome 11. The peak multipoint
LOD score of 4.6 was obtained very nearby. The segre-
gation of this gene suggests dominant inheritance.
These results reveal an important genetic e¡ect related
to discoid rash at 11p13 in African Americans with SLE,
and demonstrate, through increasing genetic homoge-
neity, the power of pedigree strati¢cation to detect link-
age in complex diseases. Keywords: discoid lesion/genome
scan/linkage/SLE. J Investig Dermatol Symp Proc 9:
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S
ystemic lupus erythematosus (SLE) is a disease of di-
verse clinical, serological, and pathologic features in
which immune responses are directed against a multi-
tude of self antigens. This astonishing variation might
be explained by the inheritance of di¡erent combina-
tions of susceptibility genes, possibly in combination with di¡er-
ent environmental factors. Evidence for a genetic basis is
established through signi¢cant familial aggregation with 7%^
12% increased risk among the ¢rst- or second-degree relatives of
a proband (Vyse andTodd, 1996), an increased concordance rate in
identical twins (15^69%) as opposed to dizygotic twins (2%^5%)
(Deapen et al, 1992), and genome scans showing moderate support
for genetic linkage in a number of genomic locations (Ga¡ney
et al, 1998; Moser et al, 1998; Shai et al, 1999; Ga¡ney et al, 2000;
Gray-McGuire et al, 2000; Magnusson et al, 2000; Kelly et al,
2002; Lindqvist et al, 2002; Harley 2002). The relative risk ratio
for the siblings of an a¡ected proband (ls) varies from 20 to 40
(Wandstrat, 2001). Signi¢cant gender di¡erences are observed in
prevalence, age at onset, premorbid conditions, clinical expres-
sion, course of illness, response to treatment, and morbid risk. In
addition, there are important racial di¡erences in disease manifes-
tations (Kelly et al, 2002; Harley, 2002). Clearly, SLE is a hetero-
geneous and complex genetic disease.
Complex genetic phenotypes are characterized by multiple loci
with multiple common susceptibility alleles that have apparently
low penetrances, with no allele being necessary or su⁄cient for
clinical disease (Lander, 1996; Chakravarti, 1999). Their identi¢ca-
tion is di⁄cult, requiring very large numbers of multiplex fa-
milies for analysis. Various combinations of contributing alleles
at multiple genes in individual patients may give the appearance
of disease phenocopies. Clinical heterogeneity of the disease may
also arise from di¡erent genotype^phenotype interactions. Con-
sequently, analysis of such diseases requires large numbers of care-
fully genotyped and phenotyped families coupled with strategies
to incorporate the locus heterogeneity into the analysis.
A clinical feature or phenotypic covariate has allowed very
complicated genetic situations to be simpli¢ed in a few notable
successes of gene discovery in complex diseases. BRCA1 is the
classic example (Miki et al, 1994). The more than 10 genes for syn-
dromic hyper- and hypotension (Lifton, 1996) are others. Strati¢-
cation based on the presence of at least one case of the follicular
variant of papillary thyroid carcinoma provided very convincing
evidence of linkage to the 2q22 region (McKay et al, 2001). A
similar approach (Samuelsson et al, 1999) found a signi¢cant
linkage to human leukocyte antigen on chromosome 6p for familial
psoriasis, although the relationship of HLA with psoriasis has
been known for many years. Recently, we found that pedigree
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strati¢cation by variable clinical features provides strong evidence
for a number of linkages (Sco¢eld et al, 2002; Nath et al, 2001;
Kelly et al, 2002; Namjou et al, 2002a; Nath et al, 2002; Sawalha
et al, 2002; Quintero-Del-Rio et al, in press;
The purpose of pedigree strati¢cation is to achieve genetic
homogeneity by reducing phenotypic and clinical heterogeneity,
by reducing heterogeneity at the loci being evaluated. If success-
ful, linkage analysis based on SLE families also containing SLE
individuals with a relevant clinical covariate has the potential to
greatly improve the detection of the susceptibility gene(s) for
SLE.
Because DLE manifestations were part of the SLE phenotype
for some patients, but not all, and because SLE and DLE are as-
sociated at the population level, we hypothesized that SLE pa-
tients and their families with DLE manifestations might be
more genetically homogeneous at loci important to DLE-related
SLE and hence would facilitate the detection of genetic linkage.
This prediction has been shown to be true, and a linkage has been
found at 11p13 in the African American pedigrees multiplex for
SLE that contain at least one a¡ected with DLE.
MATERIALS AND METHODS
SLE family ascertainment Families were recruited from all regions of
the United States and Canada. All of the SLE patients met the 1997 revised
criteria for SLE diagnosis (Tan et al, 1982; Hochberg, 1998). A detailed
procedure for recruitment of families has been described elsewhere
(Moser et al, 1998; Gray-McGuire et al, 2000). All the linkage analyses were
based only on the families multiplex (more than two a¡ected individuals)
for SLE. These families came from three major ethnic backgrounds:
European American (EA), African American (AA), Hispanic, and others.
A total of 194 SLE families were used in the analysis. Of these, 113 were
EA, 66 were AA, and 15 were Hispanic or of another self-identi¢ed group.
Strati¢cation based on the presence of discoid lupus
erythematosus To evaluate evidence of genetic linkage in DLE-related
SLE families in the present study, we identi¢ed 26 families of EA origin
and 27 families of AA origin, ascertained from the collection of 194
pedigrees multiplex for SLE through the presence of at least one SLE case
in the pedigree with DLE. SLE and DLE status were determined by
medical record review and direct patient interview. Skin biopsies were not
usually obtained. Among the EA families, 58 members were a¡ected with
SLE (average of 2.2 a¡ecteds per family), of which 32 also were alleged to
have DLE. Among the 27 AA families, 66 members were a¡ected with
SLE (average of 2.43 a¡ecteds per family), of which 34 were alleged to
have DLE. The di¡erence in proportion of SLE a¡ecteds with DLE
manifestations between EA and AA family members was not statistically
signi¢cant (w2¼ 0.051, 1 d.f. po0.82). Because many SLE linkages are race
speci¢c, however, we analyzed the data separately for the self-identi¢ed AA
and EA pedigrees. The number of families with SLE and DLE is given by
race inTable I.
Genotyping and error checking Genomic DNA was isolated from
peripheral blood cells, buccal cell swabs, mouth wash specimens, or EBV
transformed cell lines using standard methods. Methods for the
genotyping of families have been described elsewhere (Moser et al, 1998;
Gray-McGuire et al, 2000). A total of 318 microsatellite markers with an
average heterozygosity of 76% (range 56%^94%) were typed. Average
marker spacing was 11 cM (range 2^25 cM). For the initial genome scan,
we used the genetic map and intermarker distances from the Marsh¢eld
database. Prior to linkage analysis, all family relationships were con¢rmed
using RELTEST (Olson, 1999).
Pedigree simulation False positive linkages are more likely when there
are a small number of pedigrees contributing to the result. Consequently,
we simulated the ascertainment of pedigrees for strati¢cation using the
genome scan data by randomly selecting 27 of the 66 AA pedigrees
(sampling with replacement) and performing a genome scan analysis on
each set of 27 pedigrees. We generated 10,000 resampled data-sets of 27
AA pedigrees (sampling with replacement) and calculated the 2-point
LOD score using six models of inheritance.We retained the highest LOD
score for each resampled set of 27 and constructed an empirical distribution
of LOD scores. From this distribution we also calculated the observed
mean LOD score and standard deviation (SD).
Statistical analysis A w2 test was used to identify clinical and serologic
features associated with SLE with and without DLE (Table II).
To screen the genome for linkage, we ¢rst calculated 2-point LOD
scores using six models of inheritance in the parametric maximum
likelihood method (Moser et al, 1998; Gray-McGuire et al, 2000) with the
FASTLINK program (Cottingham et al, 1993). Individual pedigree^speci¢c
LOD scores were estimated at di¡erent recombination values in 0.05
increments from 0.0 (complete linkage) to 0.5 (no linkage). These
pedigree-speci¢c LOD scores were then summed together in order to
obtain the overall LOD score at each recombination value. Because the
disease a¡ects males and females di¡erentially, this di¡erence was also
incorporated in two of the models by using two separate penetrance
functions for male and female. Once we found a signi¢cant linkage to a
marker (LOD score 43.0), the optimum model was chosen from a large
set of models generated under ¢xed population prevalence. The race-
speci¢c allele frequencies were obtained from the unrelated individuals
from the colleted pedigrees. The multipoint parametric linkage analysis
was performed under both homogeneity and heterogeneity. For this we
used the GENEHUNTER program (Kruglyak et al, 1996).
RESULTS
Race-speci¢c frequencies of all 18 standard clinical and serologi-
cal criteria between SLE patients with DLE and SLE patients
without DLE are shown (Table II). None of the features is statis-
tically di¡erent between the major groups within the race. Also
notable is that thrombocytopenia is more than ¢ve times more
frequent in the SLE a¡ecteds with DLE in AA, but the sample
size is too small for even this di¡erence to be statistically relevant.
The di¡erence in proportion of SLE a¡ecteds with DLE
manifestations between 26 EA and 27 AA families was not statis-
tically signi¢cant (w2¼ 0.051, 1 d.f. po0.82). From our entire col-
lection of 194 pedigrees, however, we have 151 AA a¡ecteds and
261 EA a¡ecteds with SLE. Now the proportion of SLE a¡ecteds
with DLE manifestations between AA and EA is statistically sig-
ni¢cant: 34/151¼23% versus 32/262¼12% (w2¼ 7.47, p¼ 0.006).
Obviously, not all of the samples here are independent. In this
case, then, we may select only one patient from each pedigree
with DLE and, interestingly, the proportion is still signi¢cant:
27/66¼ 40% versus 26/113¼23% (w2¼ 6.40, p¼ 0.01).
From the initial genome scan based on 2-point linkage analy-
sis, one marker on chromosome 11, D11S1392, showed signi¢cant
evidence of linkage (LOD score¼ 5.2) only in AA pedigrees. The
cytogenetic location of this marker is 11p13.When we combined
the data between AA and EA, the LOD score at this marker was
^2.3, which clearly demonstrated no linkage with this marker.
We then maximized the model at this marker for only AA
families. This time the LOD score was increased to 5.6
(p-value¼ 3.7107). The estimated recombination fraction
where the LOD score was maximized was 0.0. The maxi-
mized model was obtained as a dominant allele (disease allele
frequency¼ 0.1) with penetrances of 65% for male and 99% for
Table I. Strati¢cation based on SLE and DLE.The ¢rst four
entries are about the total collection used to ¢nd the pedigrees
with DLE patients
Types of Families Number
AA families 66
EA families 113
Other 15
Total 194
AA families with DLE 27
SLE a¡ecteds 66
SLE a¡ecteds with DLE 32
EA families with DLE 26
SLE a¡ecteds 58
SLE a¡ecteds with DLE 32
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female. On the other hand, the LOD and HLOD scores for all
AA families were ^0.17 and 1.74, respectively, at this marker.We
did not ¢nd any statistically signi¢cant evidence of linkage in
EA families in the genome scan.
We also performed the multipoint linkage analysis considering
all the 14 markers on chromosome 11 together. This time the
maximum multipoint LOD score under the homogeneity model
was 4.3 (p-value¼ 8.710^6); under the heterogeneity model, the
LOD score was 4.6 (p-value¼ 4.210^6) with 81% of the fa-
milies being linked (a¼ 0.81). Both linkage analyses reached the
peak LOD scores, which are very close to D11S1392 (Fig 1).
We also performed a simulation experiment to evaluate our re-
sults. From the 10,000 simulations, none of the multipoint LOD
scores exceeded the value of 5.6, which gives a p-value below
0.0001. In fact, the LOD scores under the null hypothesis ranged
from ^2.07 to 3.48, the average was ^0.44, and the estimated stan-
dard deviation was 2.47.
Interestingly, earlier we detected this genomic location for SLE
susceptibility by stratifying the pedigree based on thrombocyto-
penia (Sco¢eld et al, 2002). There are eight families in common
with the present study. These eight families yielded a LOD score
of 4.5, based on the best-¢tting model (the model that yielded the
maximum LOD score of 5.6 for 27 AA families) for the present
study.We also performed a genome scan using the remaining 19
(27^8) nonthrombocytopenic families to search for additional
evidence of linkage. No new signi¢cant linkage was found in this
subgroup (data not shown).
DISCUSSION
One major SLE susceptibility locus was detected on the short
arm of chromosome 11 (11p13) by stratifying the pedigrees ac-
cording to the presence of DLE. The estimated linkage results
were signi¢cant in both 2-point and multipoint analyses (exceed-
ing the genome-wide signi¢cance criteria established by Lander
and Kruglyak in 1995 (Lander and Kruglyak, 1995). DLE is more
frequent in AA than in EA SLE patients in most studies (Jacyk
and Damisah, 1979). This is also evidenced from our study. Inter-
estingly, we earlier detected this genomic location for SLE
susceptibility by stratifying the pedigree based on thrombocyto-
penia (Sco¢eld et al, 2002). From both of these studies, it is
clearly highly likely that there is a gene that contributes the SLE
susceptibility.
One striking feature of our results is that the 11p13 putative
gene for SLE shows linkage in the AA families but not in the
EA families, although the frequency of DLE is no di¡erent be-
tween EA and AA. Clearly, the SLE susceptibility gene at this
locus is race speci¢c, a pattern similar to that seen in studies of
other complex diseases (Lernmark and Ott, 1998).
The outcome of this experiment is provocative and has led to a
search for possible candidate genes for further study. There are
several potentially interesting candidate genes located within this
genomic region (11p13), which spans the region between 31
megabases and 39 megabases (from the UCSE genome browser).
In fact, from the database search we have found seven potential
candidate genes based on their known functions in the immune
system (CD44, RAG1), apoptosis (HIPK), blood cell develop-
ment and regulation (CAT), EBV virus infection (TRAP), pre-
vious association with disease (WT1-Wilms tumor), and
epithelial cell development (EHF). At this point any of these can-
didate genes has the potential to contain a mutation or mutations
Table II. Discoid clinical features (27 AA SLE a¡ecteds with
DLE randomly selected and compared with 27 AA SLE
a¡ecteds randomly selected from pedigrees without DLE),
(26 EA SLE a¡ecteds with DLE randomly selected and compared
with 26 EA SLE a¡ecteds from pedigrees without DLE)
African-American European-American
Clinical features SLE with
DLE
(N¼ 27)
SLE without
DLE
(N¼ 27)
SLE with
DLE
(N¼ 26)
SLE without
DLE
(N¼ 26)
Malar Rash 12 9 13 12
Photosensitivity 6 5 16 13
Oral lesions 8 3 9 8
Arthritis 21 19 9 8
Pericarditis 8 6 1 4
Pleuritis 6 6 9 7
Nephritis 11 16 6 4
Neurologic 4 6 6 4
Hemolytic Anemia 2 3 3 2
Leukopenia 16 12 6 8
Lymphopenia 15 15 10 11
Thrombocytopenia 5 1 3 2
Anti-dsDNA 15 17 9 11
Anti-Sm 8 3 2 0
ACL 8 10 8 8
Anti-nRNP 15 11 4 3
Anti-Ro 9 10 7 8
Anti-La 3 3 4 3
NOTE: Clinical features are de¢ned in Tan et al (1982) or Hochberg (1997).
Anti-Sm, anti-nRNP (nuclear ribonuclear protein), anti-Ro and anti-La are
determined by Ouchterlony double immunodi¡usion. ACL is anti-cardiolipin
Figure1. Multipoint model^based linkage
assuming homogeneity (LOD score) and
heterogeneity (HLOD score) for chromosome
11 in the 27 African American pedigrees
containing one or more a¡ected members with
discoid lupus erythematosus (DLE). The marker
positions and their intermarker distances
(in cM) are, from left to right: D11S 1984-6.0-
D11S2362-8.0-D11S 1999-12.0-D11S 1981-8.0-
A34E8-13.0-D11S1392-15.0-D11S 1985-10.0-
D11S2371-10.0-D11S 2002-12.0-D11S 2000-6.0-
D11S 1986-18.0-D11S4464-12.0-D11S912-17.0-
D11S2359.
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that cause the relationship we observed in these data at 11p13. The
availability of the genome sequence and accompanying dense
SNP map will enable more exhaustive tests to pinpoint the puta-
tive susceptibility gene.
Because the presence of DLE manifestations in a family was
used as a pedigree strati¢cation criterion, and because DLE is a
major criterion for identifying the SLE phenotype, perhaps
DLE and SLE have a common autoimmune genetic determi-
nant(s). These results demonstrate that, regardless of the actual
number of genes involved in SLE, decreasing sample heterogene-
ity by subgrouping families on the basis of common associated
phenotypes has increased the likelihood of identifying genes for
SLE. To the best of our knowledge, the studies presented herein
represent the ¢rst genome-wide survey for ¢nding DLE-related
SLE susceptibility genes.
In summary, we have identi¢ed a potentially informative
genomic region at 11p13, which may contain the putative SLE
susceptibility gene. We have also demonstrated the presence of
signi¢cant genetic heterogeneity, which, when ignored, leads to
underestimation of signi¢cant linkage. We have shown signi¢-
cantly increased evidence for linkage with SLE when we sepa-
rately consider the DLE-related SLE families, a subgroup with
potentially homogeneous genetic properties.
ELECTRONIC DATABASE INFORMATION
The URLs for the database information used in this article are as
follows:
Candidate gene location for chromosome 11: http://nciarray.
nci.nih.gov/cards/index.html
Marsh¢eld database: http://research.marsh¢eldclinic.org
Lupus Multiplex Registry and Repository: http://omrf.ouhsc.
edu/lupus
Online Mendelian Inheritance in Man (OMIM): http://www.
ncbi.nlm.nih.gov/Omim/ (for SLE [MIM
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